Riskpilot← Back to searchSign inGet full accessMediRose Oy
OYDissolvedY-tunnus 2828038-2Pl 22Medical specialists activities · NACE 8622Est. 20171 employees
Revenue 2025
EUR 193K
+42% vs 2024
EBITDA margin
31.1%
-78% vs 2024
Equity ratio
44.6%
Financial strength
Net profit 2025
EUR 14K
+90% vs 2024
| Revenue | EUR 193K | +42% |
| EBITDA | EUR 60K | -78% |
| Net profit | EUR 14K | +90% |
| Total assets | EUR 417K | -2% |
| Equity | EUR 186K | +0% |
| Employees | 1 | — |
Legal name
MediRose Oy
Y-tunnus number
2828038-2
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
12. huhtikuuta 2017
Share capital
EUR 2 500
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Toimitusjohtaja yksin
Company purpose
Yhtiön toimiala on lääkäripalveluiden, kuntoutus- ja fysioterapeutin palveluiden tuottaminen potilaille, alan koulutus ja konsultointi, kustannustoiminta sekä kaikki muu laillinen liiketoiminta. Yhtiö voi omistaa, hallita ja vuokrata sekä välittää kiinteistöjä, liike- ja asuinhuoneistoja sekä kulkuneuvoja. Yhtiö voi harjoittaa arvopaperikauppaa. Yhtiö voi harjoittaa toimintaa Suomessa ja ulkomailla.
Address
Pl 22
Email
medirose.ltd@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 148 | 181 | 175 | 136 | 193 |
| Staff expenses | −40 | −21 | −31 | 59 | −45 |
| EBITDA | 48 | 83 | 66 | 268 | 60 |
| Depreciation & amort. | −23 | −19 | −15 | 25 | −23 |
| EBIT | 25 | 64 | 51 | −8 | 37 |
| Net financials | −2 | −4 | −12 | 0 | 1 |
| Profit before tax | 23 | 60 | 40 | 8 | 19 |
| Tax | 5 | 12 | 10 | 0 | −5 |
| Net profit | 18 | 48 | 30 | 8 | 14 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 308 | 403 | 39 435 | 426 | 417 |
| Equity | 142 | 179 | 19 433 | 186 | 186 |
| Long-term debt | 142 | 192 | 11 723 | 204 | 180 |
| Short-term debt | 24 | 32 | 8 279 | 36 | 51 |
| Total debt | 166 | 224 | 20 002 | 239 | 231 |
EBITDA margin
31.1%
This company
15.8%
Market median
+97% vs market
20212025
Equity ratio
44.6%
This company
38.2%
Market median
+17% vs market
20212025
Return on equity
7.7%
This company
18.4%
Market median
-58% vs market
20212025
Net profit margin
7.4%
This company
8.1%
Market median
-9% vs market
20212025
Asset turnover
0.46×
This company
1.12×
Market median
-59% vs market
20212025
Debt / equity
1.24×
This company
0.62×
Market median
-100% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via PRH / YTJ · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via PRH / YTJ · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via PRH / YTJ · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via PRH / YTJ · Period 2020-10-01 – 2021-09-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JM Deputy Member | Deputy Member | 2017 |
IT Chief Executive Officer | Chief Executive Officer | 2017 |
| Former (2) | ||
JA | Audit | 2017 – 2025 |
PR Deputy auditor | Deputy auditor | 2017 – 2025 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MediRose Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Janina Maria Rosenqvist | Deputy Member | 0 companies |
| Jose Adam Juhani Kautonen | Audit | 0 companies |
| Ilari Tapio Rosenqvist | Chief Executive Officer | 0 companies |
| Petteri Raine Lagus | Deputy auditor | 0 companies |